Straits Times Index
3,264.53 -35.51 (-1.08%) S&P 500
5,180.94 -6.76 (-0.13%) Dow
38,965.51 +81.25 (+0.21%) Nasdaq
16,280.97 -51.58 (-0.32%) Bitcoin USD
62,533.75 -951.27 (-1.50%) CMC Crypto 200
1,326.15 +31.48 (+2.43%)
Isoray Inc (AAJ.SG)
| Previous close | 1.6700 |
| Open | 1.6700 |
| Bid | 1.6100 x 500000 |
| Ask | 1.6600 x 500000 |
| Day's range | 1.6200 - 1.6700 |
| 52-week range | 0.2080 - 1.7200 |
| Volume | |
| Avg. volume | 232 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswirePerspective Therapeutics to Participate at Upcoming May Investor Conferences
SEATTLE, May 03, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in the following upcoming investor conferences as scheduled below, and will be available for one-on-one meetings with investors. Guggenheim Healthcare Talks | Radiopharmaceuticals D
- GuruFocus.com
Lantheus Holdings Inc (LNTH) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and ...
Impressive quarterly performance with significant revenue growth and strategic advancements in radiopharmaceuticals.
- GlobeNewswire
Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results
SEATTLE, May 02, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will report its first quarter 2024 financial results and provide a business update on Wednesday, May 15, 2024 before market open. The press release will be available on the newsroom section of the Company’s website at https://perspectivetherapeutics.com/newsroom/pre
